SLC1A2 and Alzheimer disease: GLT-1 immunoreactivity is reduced in the frontal cortex of AD patients (Li et al., 1997, Tian et al., 2010) and this reduction is inversely correlated with amyloid precursor protein mRNA levels, while no change has been observed for GLAST expression.